Curis, Inc. (Ticker: CRIS), located in Lexington, Massachusetts, is a biotechnology firm focused on advancing targeted therapies in oncology to meet significant unmet medical needs. The company leverages its proprietary platforms to develop a diverse pipeline of innovative drug candidates designed to improve patient outcomes across various cancer indications. With a steadfast commitment to research and development, Curis is poised to make meaningful advancements in cancer treatment, aiming to enhance the quality of life for patients facing this challenging disease. Show more

Location: BUILDING C, LEXINGTON, MA, UNITED STATES, 02421, Building C, Suite 500, Lexington, MA, 02421, USA | Website: https://www.curis.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

11.61M

52 Wk Range

$0.77 - $3.57

Previous Close

$0.91

Open

$0.92

Volume

149,550

Day Range

$0.86 - $0.93

Enterprise Value

4.691M

Cash

9.051M

Avg Qtr Burn

-5.569M

Insider Ownership

6.99%

Institutional Own.

35.56%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Erivedge (vismodegib) Details BCC (Basal Cell Carcinoma)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Emavusertib (CA-4948) (IRAK4/FLT3 Inhibitor) Details Chronic Lymphocytic Leukemia	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CA-4948 (emavusertib) Details Acute myeloid leukemia, Myelodysplastic syndrome, Blood cancer, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CA-4948 (emavusertib) + Pembrolizumab Details Melanoma	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CA-4948 (emavusertib)+/- ibrutinib Details Blood cancer, Cancer, primary central nervous system lymphomas	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Emavusertib (CA-4948) (IRAK4/FLT3 Inhibitor) Details Pancreatic Ductal Adenocarcinoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CA-4948 (emavusertib) + venetoclax + azacitidine (ema-ven-aza) Details Acute myeloid leukemia, Blood cancer, Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CI-8993 (anti-VISTA antibody) Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.